Product Description
Pentobarbital is a medication used to manage and treat several medical conditions, including seizures, intracranial pressure control, insomnia, and as a pre-anesthetic in the operating room. Pentobarbital works in the central nervous system by binding to gamma-aminobutyric acid (GABA) A subtype receptors. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK545288/)
Mechanisms of Action: GABA Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Brazil | Canada | Dominican Republic | Egypt | Germany | Hong Kong | Ireland | Korea | Malaysia | Norway | Poland | Taiwan | United States | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|